MiniMed Group, Inc. (MMED) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Excellent. Welcome, everybody, to Day-2 of the London Healthcare Conference for Bank of America. I'm Dan Lundquist, the Global Healthcare Specialist based in New York. I'm very pleased today to have MiniMed with me. We have Que Dallara, Chief Executive Officer; and Chad Spooner, Chief Financial Officer, with me up here for a fireside chat. So with that, let me kick off. Question-and-Answer Session Daniel Lundquist So maybe first, just touching on post the initial spin-off, MiniMed is entering a new phase, with recent innovation reaching patients in the broader portfolio moving increasingly toward commercialization. What's changed the most fundamentally? Why should investors view MiniMed as a growth company today? Maybe we'll start there. Que Dallara CEO & Director Well, Dan, thanks for having us. What's really fundamentally changed, I would say, is really 2 things. One is, we really kicked it up a gear. And you can see that in our last 2 quarters of -- consecutive quarters of high-single-digit, low-double-digit growth. We pushed a lot of the pipeline that we committed to at the IPO to the left, so ahead of schedule. And I think that's a lot more visible. We are a public company, and we're able to talk about it a bit more now. So I think those 2 things have been pronounced. This market is huge. It's $19 billion, growing double digit. So we're playing in a very attractive space, but an incredible pipeline that we're executing on right now. We've seen the U.S., for example, accelerate. Our international business continues to perform consistently. And so when you take all those elements together, we're not